Shares of Vectura Group PLC (LON:VEC) have received a consensus recommendation of “Buy” from the ten brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is GBX 184.17 ($2.47).
Several equities research analysts have recently commented on the stock. Shore Capital reaffirmed a “buy” rating on shares of Vectura Group in a research report on Wednesday, August 16th. Peel Hunt reaffirmed a “hold” rating and set a GBX 160 ($2.14) price target on shares of Vectura Group in a research report on Wednesday, August 16th. Numis Securities reaffirmed a “buy” rating and set a GBX 205 ($2.75) price target on shares of Vectura Group in a research report on Thursday, October 5th. Panmure Gordon reaffirmed a “buy” rating on shares of Vectura Group in a research report on Wednesday, August 30th. Finally, Citigroup reduced their price target on shares of Vectura Group from GBX 200 ($2.68) to GBX 180 ($2.41) and set a “buy” rating for the company in a research report on Monday, September 18th.
In other Vectura Group news, insider Bruno Angelici purchased 70,000 shares of the company’s stock in a transaction on Tuesday, September 12th. The stock was acquired at an average cost of GBX 99 ($1.33) per share, for a total transaction of £69,300 ($92,808.36). Also, insider Andrew Derodra purchased 82,000 shares of the company’s stock in a transaction on Thursday, September 7th. The stock was acquired at an average price of GBX 90 ($1.21) per share, with a total value of £73,800 ($98,834.87). Over the last quarter, insiders have purchased 152,456 shares of company stock valued at $14,354,880.
TRADEMARK VIOLATION WARNING: “Vectura Group PLC (VEC) Given Average Recommendation of “Buy” by Analysts” was reported by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/11/30/vectura-group-plc-vec-given-average-recommendation-of-buy-by-analysts.html.
About Vectura Group
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.